The Immediate and Longterm Immune Responses of UK Infants and Young Children to a Booster Dose of Hib Vaccine

To measure the magnitude and persistence of the antibody response to a booster dose of Hib conjugate vaccine given between 9 months and 4 years of age to UK children who had completed primary immunisation with 3 doses of Hib vaccine given at 2/3/4 months of age either as a combined D/T/wholecellpertussis/Hib or D/T/acellularpertussis/Hib vaccine.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Haemophilus Influenzae Type b Bacterial Infections Bacterial Infections and Mycoses Gram-Negative Bacterial Infections Haemophilus Infections Infections Pasteurellaceae Infections

Age range

9 month–4 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Written informed consent from parent or legal guardian of the infant or child
Age >= 9 months and <4 years at recruitment
Eligible to receive a single dose of Hib vaccine as per the UK schedule
Receipt of three doses of Hib vaccine in infancy

Exclusion criteria

History of Hib infection
History of severe local reaction that can be confidently related to a prior Hib immunisation
Deferral of vaccination if acute illness and/or temperature >38C on day of vaccination

Treatment and study plan

Hib conjugate vaccine

Biological

Sponsors and collaborators

Lead sponsor

Public Health England

Other Gov

Registry information

Important dates

Study start: 2003
Primary completion: 2005
Study completion: 2005
First posted: Sep 20, 2005
Registry last updated: Aug 24, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed